$AQST

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.

Aquestive Therapeutics (AQST) announced the FDA accepted its resubmission for Anaphylm, a treatment for Type I allergic reactions. The FDA set a PDUFA goal date of March 16, 2027. The resubmission follows positive study results addressing prior FDA concerns. If approved, Anaphylm would be the first oral rescue medication for severe allergic reactions.

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Regulation FD Disclosure. Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 • FDA accepted the resubmission as complete and classified it as a Class 2 response • Prescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027

Eton Pharmaceuticals (ETON) and Aquestive Therapeutics (AQST) signed an exclusive U.S. licensing agreement for LIBERVANT, a buccal film seizure rescue therapy. Eton gains commercialization rights, while Aquestive will manufacture. The U.S. seizure rescue market is estimated at over $450 million annually. LIBERVANT is expected to launch in April 2027, pending FDA approval. Both companies' stocks showed mixed trading activity.

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film • Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a ma

Eton Pharmaceuticals, Inc. (ETON) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT ® (diazepam) Buccal Film ● Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue tr

Eton Pharmaceuticals (ETON) and Aquestive Therapeutics (AQST) entered an exclusive license agreement for LIBERVANT, a buccal film for seizure rescue. 71% of surveyed patients preferred the film over nasal spray. The U.S. market for seizure rescue treatments exceeds $450M annually. Eton anticipates commercial launch in April 2027, subject to FDA approval. LIBERVANT has Orphan Drug Designation and patent protection until 2038.

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards

Aquestive Therapeutics (AQST) reported Q2 2026 results, staying on track to resubmit Anaphylm epinephrine film to the FDA in Q3 2026. Studies addressed FDA concerns, with improved packaging and labeling. Revenue rose 38% to $13.8M, but net loss widened to $22.9M. Cash reserves stand at $98.5M. The company also advanced its epinephrine prodrug platform and manufacturing business.

Aquestive (AQST) reported progress in its Anaphylm resubmission to the FDA, addressing previous issues with packaging and administration. The company's recent studies showed significant improvements in ease of use and effectiveness. Aquestive aims to resubmit Anaphylm before the end of the quarter and believes the product has a strong market opportunity, potentially exceeding $1 billion annually, due to its clinical differentiation and ease of use.